CN106573916A - 放射性标记的化合物 - Google Patents

放射性标记的化合物 Download PDF

Info

Publication number
CN106573916A
CN106573916A CN201580042832.2A CN201580042832A CN106573916A CN 106573916 A CN106573916 A CN 106573916A CN 201580042832 A CN201580042832 A CN 201580042832A CN 106573916 A CN106573916 A CN 106573916A
Authority
CN
China
Prior art keywords
compound
substituted
alkyl
optionally substituted
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580042832.2A
Other languages
English (en)
Chinese (zh)
Inventor
小池竜树
池田周平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN106573916A publication Critical patent/CN106573916A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nuclear Medicine (AREA)
CN201580042832.2A 2014-06-09 2015-06-08 放射性标记的化合物 Pending CN106573916A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009526P 2014-06-09 2014-06-09
US62/009,526 2014-06-09
PCT/JP2015/067100 WO2015190613A1 (en) 2014-06-09 2015-06-08 Radiolabeled compounds

Publications (1)

Publication Number Publication Date
CN106573916A true CN106573916A (zh) 2017-04-19

Family

ID=53610936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580042832.2A Pending CN106573916A (zh) 2014-06-09 2015-06-08 放射性标记的化合物

Country Status (6)

Country Link
US (1) US9963443B2 (enExample)
EP (1) EP3152198B1 (enExample)
JP (1) JP6533799B2 (enExample)
CN (1) CN106573916A (enExample)
CA (1) CA2951521A1 (enExample)
WO (1) WO2015190613A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111436396A (zh) * 2020-04-24 2020-07-24 军事科学院军事医学研究院环境医学与作业医学研究所 大鼠恐惧应激与气态污染物复合暴露模型的建立方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008591A0 (en) * 2012-12-11 2013-07-31 Takeda Pharmaceutical Heterocyclic compounds
CN114591420A (zh) 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
WO2017210302A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
US20210346366A1 (en) * 2018-09-20 2021-11-11 Takeda Pharmaceutical Company Limited Ch24h inhibitors for pain use
WO2024035925A2 (en) * 2022-08-12 2024-02-15 Emory University N-cyclopropyl-1-(4-(4-(fluoro-18f)phenyl)pyrimidin-5-yl)-n-methylpiperidine-4-carboxamide and uses in pet imaging

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013027845A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals
CN103842356A (zh) * 2011-10-07 2014-06-04 武田药品工业株式会社 用于治疗神经变性疾病的1-芳基羰基-4-氧-哌啶化合物
CA2894492A1 (en) * 2012-12-11 2014-06-19 Takeda Pharmaceuticals Company Limited Heterocyclic compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2175083T3 (es) 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
CN1379819A (zh) 1999-06-28 2002-11-13 俄克拉荷马州医学研究基金会 具有催化活性的重组memapsin蛋白酶及其应用方法
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
WO2004078732A1 (fr) * 2003-01-28 2004-09-16 Aventis Pharma S.A. Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20090029949A1 (en) * 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
WO2010110400A1 (ja) 2009-03-26 2010-09-30 武田薬品工業株式会社 複素環化合物
CN104136420A (zh) * 2011-12-15 2014-11-05 通用电气健康护理有限公司 作为tau病理学的成像探针的杂环化合物
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
EP2982670B1 (en) 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
US9908875B2 (en) * 2013-12-20 2018-03-06 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
US9624170B2 (en) * 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013027845A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (pde10a) in mammals
CN103842356A (zh) * 2011-10-07 2014-06-04 武田药品工业株式会社 用于治疗神经变性疾病的1-芳基羰基-4-氧-哌啶化合物
CA2894492A1 (en) * 2012-12-11 2014-06-19 Takeda Pharmaceuticals Company Limited Heterocyclic compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111436396A (zh) * 2020-04-24 2020-07-24 军事科学院军事医学研究院环境医学与作业医学研究所 大鼠恐惧应激与气态污染物复合暴露模型的建立方法

Also Published As

Publication number Publication date
EP3152198B1 (en) 2019-02-27
JP6533799B2 (ja) 2019-06-19
EP3152198A1 (en) 2017-04-12
US9963443B2 (en) 2018-05-08
US20170114042A1 (en) 2017-04-27
JP2017520540A (ja) 2017-07-27
CA2951521A1 (en) 2015-12-17
WO2015190613A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
US9963443B2 (en) Radiolabeled compounds
EP3436444B1 (en) Heterocyclic compound
EP3895707B1 (en) Heterocyclic compound
US10968231B2 (en) Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders
US10968178B2 (en) IP6K inhibitors
EP3210973B1 (en) Heteroaryl compounds for the treatment of ophthalmic diseases
AU2015216439A1 (en) Heterocyclic compound
US10548877B2 (en) Aromatic ring compound
EP3612527B1 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
EP2970331B1 (en) Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
US20250250230A1 (en) Heterocyclic compound
US20220089525A1 (en) Heterocyclic compound and use thereof
EP3239150A1 (en) Heterocyclic compound
EP4153583B1 (en) 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of depression
EP4046688B1 (en) Heterocyclic compound
EP4034257B1 (en) Heterocyclic compound and use thereof
HK40059391A (en) Heterocyclic compound and use thereof
HK40077256A (en) Heterocyclic compound and use thereof
HK40077256B (en) Heterocyclic compound and use thereof
HK40090317A (zh) 作为pet放射性示踪剂的[18f]-标记的咪唑幷吡啶衍生物
HK1261846B (en) Heterocyclic compound
HK1261846A1 (en) Heterocyclic compound
IL270154B (en) Heterocyclic compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170419